ecteinascidin 743 has been researched along with Disease Exacerbation in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (22.22) | 29.6817 |
| 2010's | 19 (70.37) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Avesani, G; Boccia, SM; Corrado, G; Fagotti, A; Marchetti, C; Scambia, G; Tiberi, G; Vertechy, L | 1 |
| Reichardt, P | 1 |
| Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U | 1 |
| Amoreo, CA; Biagini, R; Bon, G; Covello, R; D'Incalci, M; Del Bufalo, D; Falcioni, R; Ferraresi, V; Frapolli, R; Laquintana, V; Loria, R; Milella, M; Novello, M; Trisciuoglio, D; Zoccali, C | 1 |
| Cornillie, J; Debiec-Rychter, M; Hompes, D; Langmans, C; Schöffski, P; Sciot, R; van Cann, T; Vandenbempt, I; Wozniak, A | 1 |
| Ahrens, M; Bauer, S; Grabellus, F; Hoiczyk, M; Podleska, L; Pöttgen, C; Schuler, M; Schwindenhammer, B; Taeger, G | 1 |
| Aglietta, M; Aliberti, S; Galizia, D; Grignani, G; Nuzzo, AM; Palesandro, E; Pignochino, Y | 1 |
| Allavena, P; D'Incalci, M; Galmarini, CM | 1 |
| Cuesta, M; Guix, M; Hernández-Pastor, LJ; Lavernia, J; Villa, G | 1 |
| Bompas, E; Clisant, S; Guillemet, C; Italiano, A; Maynou, C; Penel, N; Peugniez, C; Piperno-Neumann, S; Ryckewaert, T; Saada-Bouzid, E; Taieb, S; Thyss, A; Tresch, E | 1 |
| Bay, JO; Bertucci, F; Blay, JY; Chevreau, C; Clisant, S; Delcambre, C; Domont, J; Isambert, N; Italiano, A; Le Cesne, A; Mir, O; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Ryckewaert, T; Saada-Bouzid, E; Tresch-Bruneel, E; Valentin, T | 1 |
| Cheng, PS; Favis, R; Ghatage, P; Henitz, E; Knoblauch, R; Li, W; Matos-Pita, AS; Monk, BJ; Nieto, A; Parekh, T; Park, YC; Poveda, A; Ricci, D | 1 |
| Blay, JY; Bui-Nguyen, B; Butrynski, JE; Collin, F; Isambert, N; Kerst, JM; Litière, S; Marréaud, S; Milhem, M; Penel, N; Reyners, AK; van der Graaf, WT | 1 |
| Le Cesne, A; Reichardt, P | 1 |
| Ben Mrad, M; Collard, O; Diao, P; Espenel, S; Fournel, P; Langrand-Escure, J; Magné, N; Méry, B; Moriceau, G; Rivoirard, R; Vallard, A; Wang, G | 1 |
| Araki, N; Hiraga, H; Hiruma, T; Kawai, A; Kunisada, T; Matsumine, A; Morioka, H; Sugiura, H; Takahashi, M; Takahashi, S; Ueda, T; Yonemoto, T | 1 |
| Papaioannou, D; Rafia, R; Simpson, EL; Stevenson, MD | 1 |
| Dietrich, S; Egerer, G; Ho, AD; Keller, E; Schmitt, T; Wuchter, P | 1 |
| Allavena, P; Mantovani, A | 1 |
| Aymes, A; Chawla, S; Demetri, GD; Hamm, J; Kaiser, PE; Li, J; Patel, S; Samuels, BL; Schuetze, S; von Mehren, M | 1 |
| Canniff, J; Demetri, GD; Garcia-Carbonero, R; Gomez, J; Goss, G; Guzman, C; Harmon, D; Jimeno, J; Lopez, T; Maki, RG; Manola, J; Matulonis, U; Merriam, P; Puchalski, TA; Quigley, MT; Ryan, DP; Sancho, MA; Seiden, MV; Supko, JG | 1 |
| Blay, JY; Bonvalot, S; Collin, F; Di Paola, E; Jimeno, J; Judson, I; Le Cesne, A; Lorigan, P; Nielsen, OS; Radford, J; Ray-Coquard, I; Rodenhuis, S; Van Glabbeke, M; Van Oosterom, A; Verweij, J | 1 |
| Judson, I; Le Cesne, A; Therasse, P; Van Glabbeke, M; Verweij, J | 1 |
| Alfaro, V; Casado, E; Cubedo, R; Díaz-Rubio, E; García, M; Gómez, J; Gravalos, C; Izquierdo, MA; Paz-Ares, L; Rivera-Herreros, F; Tabernero, J | 1 |
| Daniels, S; McTiernan, A; Roylance, R; Seddon, B; Sykes, K; Whelan, J | 1 |
| Brain, E; Cottu, P; Cvitkovic, E; Delaloge, S; Goldwasser, F; Jimeno, J; Marty, M; Misset, JL; Raymond, E; Riofrio, M; Taamma, A; Yovine, A | 1 |
5 review(s) available for ecteinascidin 743 and Disease Exacerbation
| Article | Year |
|---|---|
Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature.
Topics: Aged; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Humans; Leiomyosarcoma; Lung Neoplasms; Male; Renal Insufficiency; Salvage Therapy; Tetrahydroisoquinolines; Time Factors; Tomography, X-Ray Computed; Trabectedin; Treatment Outcome | 2013 |
Trabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironment.
Topics: Animals; Antineoplastic Agents; Aquatic Organisms; Cell Death; Cell Survival; Depsipeptides; Dioxoles; Disease Progression; Humans; Molecular Targeted Therapy; Neoplasms; Peptides, Cyclic; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2014 |
Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dioxoles; Disease Progression; Drug Administration Schedule; Hematologic Diseases; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Multicenter Studies as Topic; Palliative Care; Patient Selection; Randomized Controlled Trials as Topic; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Translocation, Genetic | 2015 |
Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dioxoles; Disease Progression; Health Care Costs; Humans; Kaplan-Meier Estimate; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; United Kingdom | 2010 |
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Chemotaxis; Clodronic Acid; Cytokines; Dioxoles; Disease Progression; Humans; Immunity, Innate; Inflammation; Liposomes; Macrophages; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Tetrahydroisoquinolines; Trabectedin; Tumor Escape; Tumor Microenvironment | 2012 |
11 trial(s) available for ecteinascidin 743 and Disease Exacerbation
| Article | Year |
|---|---|
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome | 2017 |
Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Substitution; Female; France; Humans; Infusions, Intravenous; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Outcome; Young Adult | 2015 |
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Dioxoles; Disease Progression; Disease-Free Survival; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Nuclear Proteins; Ovarian Neoplasms; Pharmacogenetics; Polyethylene Glycols; Tetrahydroisoquinolines; Time Factors; Trabectedin; Transcription Factors; Treatment Outcome | 2015 |
A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2015 |
Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Compassionate Use Trials; Dioxoles; Disease Progression; Female; Global Health; Health Services Accessibility; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Failure; Treatment Outcome; Young Adult | 2013 |
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Isoquinolines; Male; Middle Aged; Neoplasm Metastasis; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2004 |
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2005 |
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Humans; Isoquinolines; Prospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2005 |
Phase II study of trabectedin in pretreated patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dioxoles; Disease Progression; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Tetrahydroisoquinolines; Time Factors; Trabectedin | 2007 |
Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Disease-Free Survival; Female; Humans; Ifosfamide; Male; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Outcome; United Kingdom | 2007 |
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Dioxoles; Disease Progression; Female; Humans; Isoquinolines; Liver; Male; Middle Aged; Neutropenia; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2001 |
11 other study(ies) available for ecteinascidin 743 and Disease Exacerbation
| Article | Year |
|---|---|
Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Case-Control Studies; Disease Progression; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Trabectedin | 2023 |
Uncertainties that threaten the benefit/risk balance in early treatment lines for advanced or metastatic soft tissue sarcoma.
Topics: Aged, 80 and over; Chemoradiotherapy; Disease Progression; Fatal Outcome; Humans; Leiomyosarcoma; Lumbar Vertebrae; Lung; Lung Neoplasms; Male; Positron Emission Tomography Computed Tomography; Risk Assessment; Spinal Neoplasms; Trabectedin | 2021 |
HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance.
Topics: Antineoplastic Agents, Alkylating; Disease Progression; Drug Resistance, Neoplasm; E2F1 Transcription Factor; HMGA Proteins; Humans; Liposarcoma; NF-kappa B; Signal Transduction; Trabectedin | 2018 |
Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Doxorubicin; Female; Humans; Ifosfamide; Liposarcoma; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Tertiary Care Centers; Trabectedin; Treatment Outcome; Young Adult | 2019 |
Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Dioxoles; Disease Progression; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2013 |
Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dioxoles; Disease Progression; Drug Costs; Humans; Indazoles; Probability; Pyrimidines; Quality-Adjusted Life Years; Sarcoma; Spain; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2015 |
Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Drug Administration Schedule; Female; Humans; Image Processing, Computer-Assisted; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Tomography, X-Ray Computed; Trabectedin; Young Adult | 2015 |
What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Disease Progression; Female; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2015 |
Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Cross-Over Studies; Dioxoles; Disease Progression; Disease-Free Survival; Drug Substitution; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Randomized Controlled Trials as Topic; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Time Factors; Trabectedin; Translocation, Genetic; Treatment Failure; Young Adult | 2016 |
In brief: Two Drugs for soft-tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Furans; Humans; Ketones; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Outcome; Tubulin Modulators | 2016 |
Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Urochordata; Young Adult | 2010 |